TCR_Public/960918.MBX




InterNet Bankruptcy Library - News for September 18, 1996






Bankruptcy News For September 18, 1996



  1. Cambridge Biotech Corporation Reports on District Court Hearing




Cambridge Biotech Corporation Reports on District Court Hearing


WORCESTER, Mass., Sept. 18, 1996/ - Cambridge Biotech Corporation (OTC: CBCXQ)  
reported today that the U.S. District Court (District of Massachusetts) held a hearing on the merits  
of the appeal by Institut Pasteur and Pasteur Sanofi Diagnostics of the U.S. Bankruptcy Court's  
confirmation of CBC's plan of reorganization. Two separate appeals filed by Alfa Laval Agri  
were withdrawn prior to the hearing after the company entered into a settlement agreement with  
CBC.


The court took the matter under advisement and indicated that it expects to issue a ruling in the  
near future. The court extended the current stay of the confirmation order pending its ruling and  
ordered Pasteur to show cause why it should not be required to post an initial bond in the amount  
of $3 million if the appeal is not decided by the end of September.


Cambridge Biotech Corporation, which filed for protection under Chapter 11 of the United States  
Bankruptcy Code on July 7, 1994, is a therapeutics and diagnostics company focusing on  
infectious diseases and cancer. The Company is developing and commercializing products which  
stimulate the immune system for use in treating certain infectious diseases and specific cancers.  
The therapeutic products include the Stimulon(TM) family of adjuvants, the most advanced of  
which, QS-21, is in clinical development through corporate and academic partners, and  
proprietary vaccines. The proprietary vaccines include a feline leukemia vaccine currently on the  
market, and in development human vaccines for pneumococcal infections, malaria and tick-borne  
diseases, and animal vaccines for bovine mastitis and canine Lyme disease. Cambridge Biotech's  
diagnostic business is primarily focused on retroviral and Lyme diseases.


Statements in this release which relate to plans and objectives of management for future  
operations or which otherwise relate to future performance are forward looking statements.  
Actual results may differ from those projected as a result of the Company's success in emerging  
from bankruptcy, product demand, pricing, market acceptance, the effect of economic conditions,  
intellectual property, competitive products, risks in product and technology development, and  
other risks identified in the Company's Securities and Exchange Commission filings.


SOURCE Cambridge Biotech Corporation/CONTACT: Alison Taunton-Rigby, President, Chief  
Executive Officer of Cambridge Biotech Corporation, 508-797-5777, or Robert Gottlieb of  
Senior Vice President of Feinstein Partners, Inc., 617-577-8110/ (CBCXQ)